Trials / Completed
CompletedNCT04336449
Eptinezumab in Healthy Japanese Subjects
Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Eptinezumab in Healthy Japanese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate how eptinezumab enters, moves through and exits the body. Safety and tolerability will also be investigated.
Detailed description
The study will consist of 18 healthy Japanese subjects, divided into two single dose cohorts with 9 subjects in each cohort.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eptinezumab | Eptinezumab - single intravenous infusion |
| DRUG | Placebo | Placebo - single intravenous infusion |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2020-08-13
- Completion
- 2020-08-13
- First posted
- 2020-04-07
- Last updated
- 2020-08-14
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04336449. Inclusion in this directory is not an endorsement.